Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2017

01-07-2017 | Editorial

Does pasireotide directly modulate skeletal muscle metabolism?

Authors: Federico Gatto, Tullio Florio

Published in: Endocrine | Issue 1/2017

Login to get access

Excerpt

Cushing’s Disease (CD) is a severe endocrine disease caused by corticotroph pituitary adenomas. CD is associated to high mortality primarily dependent on cardiovascular comorbidities induced by glucocorticoid (GC) excess-related metabolic changes [1]. …
Literature
1.
2.
3.
C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146(5), 707–716 (2002)CrossRefPubMed
4.
R. Cescato, K.A. Loesch, B. Waser, H.R. Macke, J.E. Rivier, J.C. Reubi, A. Schonbrunn, Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol. Endocrinol. 24(1), 240–249 (2010). doi:10.​1210/​me.​2009-0321 CrossRefPubMed
5.
6.
S. Moatassim-Billah, C. Duluc, R. Samain, C. Jean, A. Perraud, E. Decaup, S. Cassant-Sourdy, Y. Bakri, J. Selves, H. Schmid, Y. Martineau, M. Mathonnet, S. Pyronnet, C. Bousquet, Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts. Oncotarget 7(27), 41584–41598 (2016). doi:10.​18632/​oncotarget.​9296 CrossRefPubMedPubMedCentral
7.
G. Tulipano, L. Faggi, S. Schulz, M. Spinello, A. Giustina, Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells. Endocrine (2017). doi:10.​1007/​s12020-017-1235-3 CrossRefPubMed
8.
9.
M.C. Zatelli, D. Piccin, C. Vignali, F. Tagliati, M.R. Ambrosio, M. Bondanelli, V. Cimino, A. Bianchi, H.A. Schmid, M. Scanarini, A. Pontecorvi, L. De Marinis, G. Maira, E.C. degli Uberti, Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 14(1), 91–102 (2007). doi:10.​1677/​ERC-06-0026 CrossRefPubMed
10.
A. Ibanez-Costa, E. Rivero-Cortes, M.C. Vazquez-Borrego, M.D. Gahete, L. Jimenez-Reina, E. Venegas, A. de la Riva, M.A. Arraez, I. Gonzalez-Molero, H.A. Schmid, S. Maraver-Selfa, I. Gavilan-Villarejo, J.A. Garcia-Arnes, M.A. Japon, A. Soto, M.A. Galvez, R.M. Luque Huertas, J.P. Castano, Octreotide and Pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J. Endocrinol. (2016). doi:10.​1530/​JOE-16-0332 CrossRefPubMed
Metadata
Title
Does pasireotide directly modulate skeletal muscle metabolism?
Authors
Federico Gatto
Tullio Florio
Publication date
01-07-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1291-8

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue

Original Article

Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses

Review

Androgenetic alopecia: a review

Original Article

Ultrasound-guided fine needle aspiration versus core needle biopsy: comparison of post-biopsy hematoma rates and risk factors

Endocrine Imaging

“Pseudo-progression” in advanced thyroid cancer in response to kinase inhibitor therapy

Endocrine Trials

The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial

Research Letter

Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits